Carcinoma  >>  Tookad (padeliporfin)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tookad (padeliporfin) / ImPact Biotech
NCT01573156 / 2011-003311-27: Vascular Targeted Photodynamic Therapy T1a Renal Tumours

Terminated
2a
5
Europe
Light activated WST11, Tookad Soluble
University of Oxford, Steba Biotech S.A.
Renal Cancer
05/14
06/15
NCT00974662 / 2009-011895-31: Study Using WST11 in Patients With Obstructing Endobronchial Non-Small Cell Lung Cancer

Terminated
2
3
Europe
WST11, WST11-mediated VTP
Steba Biotech S.A.
Non-Small Cell Lung Cancer
11/10
12/11
NCT00707356 / 2008-000876-26: Study of WST11 in Patients With Localized Prostate Cancer

Completed
2
42
Canada, Europe
WST11, WST11-mediated VTP
Steba Biotech S.A.
Prostate Cancer
01/11
07/12
NCT00975039 / 2009-011897-14: Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma

Terminated
2
8
Europe
WST11, WST11-mediated VTP
Steba Biotech S.A.
Cholangiocarcinoma
06/11
09/12
NCT00975429 / 2009-012809-19: Study Using WST11 in Patients With Localized Prostate Cancer

Completed
2
86
Europe
WST11, Treatment with WST11-mediated VTP
Steba Biotech S.A.
Prostate Cancer
12/11
08/12
NCT00946881: Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer

Completed
1/2
30
US
WST 11 -mediated -VTP, TOOKAD Soluble
Steba Biotech S.A.
Prostate Cancer
07/12
08/12

Download Options